Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Westeel

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Kidney International. Supplement|October 1, 1992
Use of alkaline calcium salts as phosphate binder in uremic patientsA Fournier, P Morinière, F Ben Hamida, et al.
Annales De Medecine Interne|January 1, 1990
[Epidemiology of primary glomerulonephritis in Picardie]Z Abdulmassih, R Makdassi, N Bove, et al.
Contributions to Nephrology|January 1, 1988
Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experienceP Morinière, A Fournier, P F Westeel, et al.
Presse Medicale (Paris, France : 1983)|October 21, 1998
[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level]A Fournier, P Yverneau-Hardy, A Ghazali, et al.
Nephron|January 1, 1992
Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2P Mornière, C Maurouard, B Boudailliez, et al.
Annales De Medecine Interne|January 1, 1989
[Efficacy of danazol in the treatment of thrombopenia in a chronic HIV-seropositive hemodialyzed patient. Unexpected appearance of major hyperglycemia]P Morinière, S Gross, J D Lalau, et al.
Nephron|January 1, 1992
Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemiaP Morinière, M Djerad, B Boudailliez, et al.
Nephron|January 1, 1995
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administrationA Fournier, P H Morinière, R Oprisiu, et al.
Nephrologie|January 1, 1991
[Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia]M Djerad, P Morinière, P F Westeel, et al.
Nephron|January 1, 1989
Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminumP Morinière, M Cohen-Solal, S Belbrik, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Kidney International. Supplement|October 1, 1992
Use of alkaline calcium salts as phosphate binder in uremic patientsA Fournier, P Morinière, F Ben Hamida, et al.
Annales De Medecine Interne|January 1, 1990
[Epidemiology of primary glomerulonephritis in Picardie]Z Abdulmassih, R Makdassi, N Bove, et al.
Contributions to Nephrology|January 1, 1988
Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experienceP Morinière, A Fournier, P F Westeel, et al.
Presse Medicale (Paris, France : 1983)|October 21, 1998
[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level]A Fournier, P Yverneau-Hardy, A Ghazali, et al.
Nephron|January 1, 1992
Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2P Mornière, C Maurouard, B Boudailliez, et al.
Annales De Medecine Interne|January 1, 1989
[Efficacy of danazol in the treatment of thrombopenia in a chronic HIV-seropositive hemodialyzed patient. Unexpected appearance of major hyperglycemia]P Morinière, S Gross, J D Lalau, et al.
Nephron|January 1, 1992
Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemiaP Morinière, M Djerad, B Boudailliez, et al.
Nephron|January 1, 1995
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administrationA Fournier, P H Morinière, R Oprisiu, et al.
Nephrologie|January 1, 1991
[Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia]M Djerad, P Morinière, P F Westeel, et al.
Nephron|January 1, 1989
Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminumP Morinière, M Cohen-Solal, S Belbrik, et al.
Pageof 9